Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 9 clinical trials
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

The purpose of this study is to evaluate the objective response rate (complete response [CR]+ partial response [PR]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.

renal function
dose regimen
erdafitinib
measurable disease
adjuvant chemotherapy
  • 40 views
  • 17 Sep, 2021
  • 158 locations
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor

carcinoma
growth factor
advanced urothelial carcinoma
adjuvant chemotherapy
transitional cell carcinoma
  • 271 views
  • 19 Sep, 2021
  • 594 locations
A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

The purpose of this study is to: (a) characterize the safety and tolerability of and to identify the recommended Phase 2 dose (RP2D) and schedule for erdafitinib in combination with cetrelimab

metastasis
systemic therapy
growth factor
measurable disease
advanced urothelial carcinoma
  • 95 views
  • 15 Sep, 2021
  • 207 locations
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

The purpose of this study is to evaluate the efficacy of erdafitinib in terms of overall response rate (ORR) in adult and pediatric participants with advanced solid tumors with fibroblast growth

solid tumour
measurable disease
growth factor
cancer
  • 39 views
  • 20 Sep, 2021
  • 268 locations
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gu rin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

The purpose of this study is to evaluate recurrence-free survival (RFS) in participants treated with erdafitinib vs Investigator's Choice, for participants with high-risk non-muscle-invasive

mitomycin
human chorionic gonadotropin
bladder cancer
carcinoma
growth factor
  • 0 views
  • 18 Sep, 2021
  • 201 locations
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer

This phase II trial studies how well erdafitinib in combination with abiraterone acetate or enzalutamide works in treating patients with double negative prostate cancer. Erdafitinib may stop the

serum testosterone
adenocarcinoma
testosterone level
gilbert's syndrome
metastasis
  • 0 views
  • 23 Jun, 2021
  • 1 location
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread to other places in

autologous stem cell infusion
neutrophil count
pegfilgrastim
cns neoplasm
cytotoxic chemotherapy
  • 261 views
  • 22 Aug, 2021
  • 82 locations
  • 12 views
  • 01 Jul, 2021
  • 3 locations
FGFR Inhibitor in FGFR Dysregulated Cancer

erdafitinib. Archival samples, fresh frozen tumor samples and blood for circulating tumor DNA (ctDNA) will be collected before treatment. Patients will be treated until disease progression or unacceptable

carcinoma
growth factor
lung carcinoma
FGFR1
cancer
  • 4 views
  • 26 Jan, 2021
  • 13 locations